Many pharmaceutical companies are trying to break into the cannabis game, but now one company's been created with the sole purpose of treating diseases using marijuana.
Stanford University researchers Jonathan Rothbard and Lawrence Steinman created a new company called Katexco Pharmaceuticals that will create medicines targeting cannabis receptors. Many people know that cannabis can help reduce inflammation, and that's largely due to cannabinoids connecting to different receptors in the brain that trigger an anti-inflammatory response. These researchers are going to use those receptors to treat a number of inflammation based conditions.
"The link between the cannabinoid pathway and anti-inflammatory effects is unprecedented, and we are beginning to understand more fully just how the body regulates itself," said Rothbard. "The goal is to ultimately develop a whole new class of compounds that target several disorders with anti-inflammatory indications.”
The researchers believe that their cannabis-based medications will be cheaper and more accessible to consumers than other medications already on the market. They also believe that the growing cannabis industry in the United States will also allow them to easily gain a foothold.
Sounds like this drug will only be a gateway to better health.